Precision Therapeutics (Formerly Known as Skyline Medical)

94 articles about Precision Therapeutics (Formerly Known as Skyline Medical)

• Skyline Therapeutics Receives China NMPA's Approval of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration

  10/19/2023

  Skyline Therapeutics announced that the China National Medical Products Administration has approved its Investigational New Drug application for SKG0106, a one-time intravitreally delivered AAV gene therapy for the treatment of neovascular age-related macular degeneration.

• 

  9 Smaller Biotechs in the Spotlight for Next Week's Q3 Reports

  11/9/2018

  Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
• 

  Meet Precision Therapeutics, An Unloved Medtech With Significant Upside Potential

  2/6/2018

  A look at Precision Therapeutics' upcoming catalysts.

• Precision Therapeutics, Formerly Skyline Medical, Announces Stock Ticker Symbol Change to AIPT

  2/2/2018

  Change in ticker symbol reflects Company’s market positioning as leaders in the AI for precision medicine market.

• Skyline Medical Projects 100 STREAMWAY System Sales in the U.S. in 2018

  1/31/2018

  2018 projection would represent a 10x increase over 2017 sales.

• Skyline Medical Opens New European Headquarters to Drive International Sales of the STREAMWAY System

  1/26/2018

  Mr. Rasschaert will be responsible for overseeing sales of the Company’s FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal to hospitals and medical centers across Europe.

• Skyline Medical Announces Corporate Name Change to Precision Therapeutics

  1/25/2018

  The new name has been chosen to better reflect the Company’s new strategic focus on applying artificial intelligence to precision medicine and drug discovery and marks a new chapter of the Company’s growth.

• Skyline Medical Completes Purchase of Preferred Stock in Helomics Corporation

  1/16/2018

  In addition, Skyline has the right to convert a previous $500,000 loan to Helomics into a further 5% equity stake, which would bring its total ownership to 25%.

• Skyline Medical Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

  1/12/2018

  The Company regained compliance with the stockholders' equity requirement as a result of the completion of two successful financings.

• Skyline Medical Announces Pricing of Firm Commitment Public Offering of Common Stock and Warrants

  1/8/2018

  Dawson James Securities, Inc. is acting as the sole underwriter for the offering.

• Skyline Medical Provides Sales Update on the STREAMWAY System

  1/4/2018

  Ten STREAMWAY units sold in 2017; six unit sales booked in January 2018.

• Skyline Medical and Helomics Expand into Next Generation Sequencing for Personalized Medicine

  12/20/2017

  Skyline Medical, producer of the FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal, today announced that it is expanding into NGS through the licensing of an NGS platform MiSeqDx, from Illumina.

• Skyline Medical Acquiring Up to 25% Equity Stake in Helomics Corporation, a Precision Diagnostics Company

  12/20/2017

  Under the terms of the agreement, Skyline Medical is purchasing preferred stock convertible into 20% of the outstanding common stock of Helomics, representing 20% of the company, in exchange for total consideration of 1.1 million shares of newly issued Skyline common stock.

• Skyline Medical Issues Letter to Shareholders

  12/8/2017

  The company laid out some of the plans Skyline’s management team has been working toward over the past several months.

• Skyline Medical Announces the Completion of Private Placement for Gross Proceeds of $1,300,000

  12/1/2017

  The closing of the private placement occurred on November 28, 2017.

• Skyline Medical and Helomics Announce a Joint Strategic Partnership With GLG Pharma

  11/28/2017

  Companies to form a partnership for cell capture, culture and drug screening for ovarian and breast cancer patients.

• Skyline Medical and Helomics Corporation Sign Joint Venture Term Sheet to Build-Out and Commercialize the D-CHIP Platform

  11/15/2017

  The joint venture follows a strategic collaboration between Helomics and Skyline announced on November 1, 2017 and represents a deeper partnership between the two companies that is expected to provide Skyline with opportunities to generate revenues from additional markets.

• Skyline Medical to Hold Business Update Conference Call on November 15, 2017

  11/13/2017

  Management will hold a conference call to provide a business update and host a discussion on recent and upcoming milestones.

• Skyline Medical Signs Distribution Agreement to Market STREAMWAY System in Australia and New Zealand

  11/10/2017

  This distribution agreement is the latest milestone in our international expansion strategy, and follows the recent signing of partnerships with two independent distributors in Canada and Switzerland.

• Skyline Medical Announces Two Proposed Joint Ventures and New Strategic Focus on CRO Services

  11/8/2017

  New collaborations with Helomics and CytoBioscience to diversify Skyline's operations into the rapidly growing CRO Services sector.